Clinical Competition Candidate
NINLARO
NINLARO carries substance and product and use-code patents, moderate complexity (3/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 40 months away. Active clinical competition may compress the generic entry window.
LOE window
40months
to latest listed patent expiry (November 20, 2029)
Expiry attractiveness: 4/5
Patent profile
Substance patent (listed)
Product / formulation patent (listed)
Use-code patent (listed)
Patent count: 7
Complexity score: 3/5
Clinical competition
Score: 5/5
Active trials linked: 167
Phase 2/3 trials: 113
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: IXAZOMIB CITRATE
Applicant (NDA holder): TAKEDA PHARMACEUTICALS USA INC
Confidence: High